(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
First Alert: Light snow through this evening - 25 Worldwide Road Food varieties You Should Attempt
- 3Spotify Wrapped and Apple Music Replay are here: Top songs, albums and artists of 2025
- 4Israel, Gulf states report fresh missile and drone attacks
- 5Building an Individual Brand: Illustrations from Powerhouses
- Vote In favor of Your #1 sort of film
- Help Your Efficiency: 10 Authoritative Apparatuses to Attempt
- The breakout star of NASA's Artemis 2 moon mission isn't an astronaut — it's the space toilet
- EU calls on Western Balkans to step up reforms for membership
- Whale stranded off Germany for days is stuck again
- Iran war drives global fertilizer prices up, raising food cost fears
- Astounding Treehouses All over the Planet
- Former Israeli judge does not expect Netanyahu to be pardoned
- UN rights chief: Israel's new Gaza aid agency rules 'outrageous'
